Skip to main content
Erschienen in: International Journal of Hematology 2/2021

25.03.2021 | Case Report

ETV6-related thrombocytopenia associated with a transient decrease in von Willebrand factor

verfasst von: Yuri Kanamaru, Toru Uchiyama, Tadashi Kaname, Kumiko Yanagi, Osamu Ohara, Shinji Kunishima, Akira Ishiguro

Erschienen in: International Journal of Hematology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

ETV6-related thrombocytopenia is an autosomal dominant thrombocytopenia, characterized by a bleeding tendency and predisposition to hematological malignancies. The similarity in symptoms makes differentiating immune and congenital thrombocytopenia challenging. We report a 5-year-old girl who presented with chronic thrombocytopenia associated with repetitive and long-lasting epistaxis, leading to blood transfusion for severe anemia. Blood tests showed thrombocytopenia (52 × 103/µL) with normal-sized platelets and transiently low von Willebrand factor (VWF) levels (VWF:RCo 13%, VWF:Ag 50%); therefore, von Willebrand disease type 2 was initially suspected. Repetition of the blood tests revealed normal levels of VWF. Exome and Sanger sequencing identified a germline ETV6 heterozygous variant, c.641C > T:p.(P214L). No additional pathogenic variants were found, including VWF, in the gene panel testing of the 53 known target causative genes for thrombocytopenia. High-throughput exome sequencing for chronic thrombocytopenia can be utilized to differentially diagnose ETV6-related thrombocytopenia from chronic/intractable immune thrombocytopenia and to effectively monitor malignancy.
Literatur
1.
Zurück zum Zitat Poggi M, Canault M, Favier M, Turro E, Saultier P, Ghalloussi D, et al. Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulation CD34+ progenitors. Haematologica. 2017;102:282–94.CrossRef Poggi M, Canault M, Favier M, Turro E, Saultier P, Ghalloussi D, et al. Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulation CD34+ progenitors. Haematologica. 2017;102:282–94.CrossRef
2.
Zurück zum Zitat Noetzli L, Lo RW, Lee-Sherick AB, Callaghan M, Noris P, Savioa A, et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015;47:535–8.CrossRef Noetzli L, Lo RW, Lee-Sherick AB, Callaghan M, Noris P, Savioa A, et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015;47:535–8.CrossRef
3.
Zurück zum Zitat Moriyama T, Metzger ML, Wu G, Nishii R, Qian M, Devidas M, et al. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukemia: a systematic genetic study. Lancet Oncol. 2015;16:1659–66.CrossRef Moriyama T, Metzger ML, Wu G, Nishii R, Qian M, Devidas M, et al. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukemia: a systematic genetic study. Lancet Oncol. 2015;16:1659–66.CrossRef
4.
Zurück zum Zitat Melazzini F, Palombo F, Balduini A, De Rocco D, Marconi C, Noris P, et al. Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia. Haematologica. 2016;101:1333–42.CrossRef Melazzini F, Palombo F, Balduini A, De Rocco D, Marconi C, Noris P, et al. Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia. Haematologica. 2016;101:1333–42.CrossRef
5.
Zurück zum Zitat Di Paola J, Porter CC. ETV6-related thrombocytopenia and leukemia predisposition. Blood. 2019;134:663–7.CrossRef Di Paola J, Porter CC. ETV6-related thrombocytopenia and leukemia predisposition. Blood. 2019;134:663–7.CrossRef
6.
Zurück zum Zitat Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SCC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8:2063–5.CrossRef Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SCC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8:2063–5.CrossRef
7.
Zurück zum Zitat Fujiki R, Ikeda M, Yoshida A, Maeda A, Yao Y, Nishimura A, et al. Assessing the accuracy of variant detection in cost-effective gene panel testing by next-generation sequencing. J Mol Diagn. 2018;20:572–82.CrossRef Fujiki R, Ikeda M, Yoshida A, Maeda A, Yao Y, Nishimura A, et al. Assessing the accuracy of variant detection in cost-effective gene panel testing by next-generation sequencing. J Mol Diagn. 2018;20:572–82.CrossRef
8.
Zurück zum Zitat Zhang MY, Churpek JE, Keel SB, Walsh T, Lee MK, Loeb KR, et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet. 2015;47:180–5.CrossRef Zhang MY, Churpek JE, Keel SB, Walsh T, Lee MK, Loeb KR, et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet. 2015;47:180–5.CrossRef
9.
Zurück zum Zitat Feurstein S, Godley LA. Germline ETV6 mutations and predisposition to hematological malignancies. Int J Hematol. 2017;106:189–95.CrossRef Feurstein S, Godley LA. Germline ETV6 mutations and predisposition to hematological malignancies. Int J Hematol. 2017;106:189–95.CrossRef
10.
Zurück zum Zitat Lavin M, O’Donnell JS. How I treat low von Willebrand factor levels. Blood. 2019;133:795–804.CrossRef Lavin M, O’Donnell JS. How I treat low von Willebrand factor levels. Blood. 2019;133:795–804.CrossRef
11.
Zurück zum Zitat Lavin M, Aguila S, Schneppenheim S, Dalton N, Jones KL, O’Sullivan JM, et al. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood. 2017;130:2344–53.CrossRef Lavin M, Aguila S, Schneppenheim S, Dalton N, Jones KL, O’Sullivan JM, et al. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood. 2017;130:2344–53.CrossRef
12.
Zurück zum Zitat O’Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulation von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol. 2002;22:335–41.CrossRef O’Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulation von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol. 2002;22:335–41.CrossRef
Metadaten
Titel
ETV6-related thrombocytopenia associated with a transient decrease in von Willebrand factor
verfasst von
Yuri Kanamaru
Toru Uchiyama
Tadashi Kaname
Kumiko Yanagi
Osamu Ohara
Shinji Kunishima
Akira Ishiguro
Publikationsdatum
25.03.2021
Verlag
Springer Singapore
Erschienen in
International Journal of Hematology / Ausgabe 2/2021
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-021-03136-4

Weitere Artikel der Ausgabe 2/2021

International Journal of Hematology 2/2021 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.